D. W. MURRAY, A. R. BRITTON, C. J. K. BULSTRODE. From the Nuffield Orthopaedic Centre, Oxford, England. The recommendation that patients having a total hip replacement should receive pharmacological thromboprophylaxis is based on the belief that fata
stable (greater than the control) when walking over barriers as was roll for the sit-to-stand task, indicative of ... after total hip replacement regarding the risk of a fall, especially in the elderly. Most patients ... metre cable to a computer whi
Marc E. Umlas. From the Centre for Total Joint Replacement, New York, USA. We report 16 cases of erythematous eruption on the skin within the flaps of the ...
Apr 29, 2013 - ing total hip replacement, and they were likely to change coital positions. The most common concern regarding sexual activity of patients was ...
flap, following damage to the inferior branch of the superior gluteal nerve, or by failure ... flap, was used in 29 hips, and the posterior. (P) .... was undisplaced.
Jul 18, 2016 - Dislocation With Fracture of Posterior Column and Wall of the ... Conclusions: A neglected hip dislocation with acetabular fracture can be ...
impingement after THR, to assess the results of surgical ... dysplasia in five patients (five hips). .... dislocation of the hip, a superficial wound infection and five .... Meyer JD, PlÃ¶tz W, Tillmann K, Russlies M. Iliopsoas impingement after ceme
arthroplasty. After total hip replacement recurrent dislocation is a serious and ..... to incorrect positioning of prosthetic components, loosening of the trochanter.
hip replacement performed after fixation failed for femoral neck fracture. (A) (n = .... of femoral loosening discovered at review. No acetabular cups were loose.
We compared the radiographic results of secondary total hip replacements,. 99 following failed uncemented hemiarthroplasties and 21 following failed.
Consultant Plastic Surgeon. â« G. C. Bannister, MD,. FRCS(Orth), Professor of. Orthopaedic Surgery. North Bristol Trust. Avon Orthopaedic Centre,. Southmead Hospital, Bristol ... appearance of the scar at three months using a surgeon-rated visual an
Anne McMurray, PhD, RN, FRCNA, Professor of Nursing,. Research Centre .... significance. This level was achieved using a Bonferroni. Correction to reduce the probability of making a Type I error when performing multiple tests. For single tests, the .
Girdlestone type of pseudarthrosis. The infection may not present for a considerable period after operation, though relatively few cases occur after one year ( ...
1 -Radiograph before operation. Figure. 2-Twelve months after operation. Figure. 3-Sinogram two years after operation. Figure. 4-After a Girdlestone operation.
Bilateral protrusio acetabuli following pelvic irradiation. J Rheumatol 1977;4:189-96. Hasselbacher P, Schumacher HR. Synovial fluid eosinophilia following.
In 1985 Galante pleaded that âorthopaedic surgeons should agree to a uniform method of evaluating and reporting the results of hip replacement surgeryâ. 1.
October 2006. Intra-articular injections of steroid into the hip are used for a variety of reasons in current .... A diagnosis of trochanteric bursitis was made and the ...
The results of previous ... (THR), and 7â14 days for patients having major knee surgery. (TKR) (5). ... New anticoagulants after hip or knee replacement. Figure 1.
biocompatible is the titanium alloy extra low interstitial (ELI)2 Tiâ6Alâ4V; its composi- tion is 90 wt% Ti, 6 wt% Al, and 4 wt% V. The optimal properties for this material are produced by hot forging; any subsequent deformation and/or heat treat
and the types of arthroplasty performed are shown in Tables. II and ... arthroplasties performed. Number of ..... in all 12 a Girdlestone arthroplasty was performed.
Abstract: Instability after total hip arthroplasty (THA) is not a rare occurrence. Numerous factors have been associated with dislocation including surgical approach, implant design, failure to restore proper hip mechanics and soft tissue restraints,
V early osteointegration. On-growth of bone to porous coated prostheses is ... rich femoral component or with the ce- ... total hip arthroplasty in dogs (1, 2). Loo-.
Radiological analysis assessing heterotopic ossification, femoral osteolysis and femoral stem ... following total joint replacement.12 A retrospec- tive study by ...
Total hip replacement (THR) is a very common procedure undertaken in up to 285 000 .... diagnosis can include activity-related pain, aseptic loosening,.
Journal of Orthopaedic Surgery 2010;18(1):92-7
Review article: Thromboprophylaxis after total hip replacement Andrew P Kurmis1,2
Department of Orthopaedic Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia 2 School of Medicine, Flinders University, Bedford Park, South Australia, Australia
ABSTRACT The risk of secondary haematologic complications such as deep vein thrombosis or pulmonary embolism increases significantly when a transient period of hypercoagulability is induced after total hip replacement (THR). A number of drug-based anticoagulant approaches are available to modulate this risk, but the optimal length of therapy for such approaches remains unclear. The literature was reviewed for evidence-based support of the routine use of an extended course (>14 days) of thromboprophylaxis after THR. Electronic databases and real-time online literature searches were performed, using the PubMed (Medline), EMBASE, CINAHL and GoogleScholar, and the Cochrane and British Medical Journal Clinical Evidence libraries. Author-defined key word searches were performed. Only articles in the English language, for which full text could be retrieved, were reviewed. There is robust evidence to support an extended course (>14 days) of thromboprophylaxis after THR. Such recommendations have been translated into the guidelines of key professional bodies, including those of the American College of Chest Physicians. Meta-
review suggests a clear benefit of such regimens and supports wider adoption, even when weighed against a small increase in adverse events. Key words: anticoagulants; arthroplasty, replacement, hip; pulmonary embolism; venous thrombosis
INTRODUCTION A transient period of hypercoagulability can occur during and after major orthopaedic surgery.1,2 There is no universally accepted postulate to account for this phase of haematologic homeostatic dysregulation. A safe and efficacious anticoagulation regimen is necessary, as the demands for joint replacement surgery worldwide,3,4 the societal and patient demands for improved outcomes, and the need for evidencebased medicine-guided practices increase.5–7 Both pharmacologic and non-pharmacologic options are available for prevention of venous thromboembolic events (VTEs).8–12 The combined use of both confers synergistic utility,3,8,12–14 whereas their individual use is rare.9,15 Optimisation of standards of care in nonpharmacologic approaches has been indicated.3,16 All available pharmacological thromboprophylaxis regimens have a risk profile.3,16,17 The literature was
Address correspondence and reprint requests to: Dr Andrew P Kurmis, Department of Orthopaedic Surgery (L7 East), Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, 3050, Australia. E-mail: [email protected]
Vol. 18 No. 1, April 2010
METHODS The PubMed (Medline), EMBASE, CINAHL and GoogleScholar, and the Cochrane and British Medical Journal Clinical Evidence libraries were searched using the key words: arthroplasty, total hip replacement, THR, thromboprophylaxis, and/or thrombo*.
VENOUS THROMBOEMBOLIC EVENTS THR is a commonly performed and ever-increasing orthopaedic procedure worldwide.16,18–20 Its demand is driven by refinements in implant design and surgical technique, increase in population life-expectancy, and increase in patient expectations in functional quality of life.19,21,22 Although THR can reduce pain and improve movement and function,16,20,22–25 it is an invasive procedure and has risks and complications,26 particularly postoperative formation of intravascular blood clots.16,27–32 VTEs can result in a high degree of morbidity and/or mortality related to pelvic and lower-limb deep vein thrombosis (DVT) and pulmonary embolism (PE).8,26–28,31,33–37 Without prophylaxis, VTE has an estimated incidence of 40 to 60%,3,17,38–40 and an event rate warranting medical attention of 1.6 to 6.4%.8,27,38,40,41 Stratification of the risks to identify patients most in need of vigilant monitoring or aggressive prophylactic therapy has been undertaken.8,42 Nonetheless, inconsistency in the definition of a VTE and disparity between clinical43 and subclinical44 (research) applications render comparisons between studies difficult, whereas biased statistical analysis may reflect both frank and sub-clinical VTEs.7 Using invasive diagnostic tools,37,45,46 the true prevalence of VTEs far exceeds that of patients who are symptomatic,3,10,40,47 which only serves to draw yet more attention to the induction of a hypercoagulable state after THR.48
EXTENDED COURSE OF THROMBOPROPHYLAXIS Recommendations for the duration of anti-VTE
therapy vary from 14 to 42 days,8,27,28,32,33,37,41,42,49–54 but their translation into clinical practice has been inconsistent.5,14,49,55,56 After THR, a thromboprophylactic regimen of >14 days has been advocated by many international bodies. For example the American College of Chest Physicians (ACCP) supports an extended course of prophylaxis with low-molecularweight heparin (LMWH) or warfarin for 28 to 35 days.32,39,42,56–61 Compared with placebo, LMWH has been shown to reduce overall VTE rates significantly (Fig.).32 An extended course (4–6 weeks) of prophylaxis is superior to placebo in reducing the incidence of symptomatic VTEs (1.3% vs. 3.3%, p<0.05, relative risk reduction [RRR]=61%, number needed to treat [NNT]=50) as well as asymptomatic VTEs (9.6% vs. 19.6%, p<0.05, RRR=51%, NNT=10).62 Compared with placebo, an extended course (4 weeks) of LMWH reduces the incidence of symptomatic VTEs from 4.2% to 1.4% (p<0.001, RRR=67%, NNT=36), and the overall rate from 22.5% to 7.9% (p<0.001, RRR=65%, NNT=7) [Table].5 Moreover, asymptomatic VTEs increase the risk of developing post-thrombotic syndrome (RR=2.36; 95% CI, 1.64–3.41; p<0.001).63 The negative impact of extended courses of VTE prophylaxis on outcomes (i.e. number needed to harm [NNH]) is difficult to determine, because of the low frequency of such adverse events.7,58 The rate of minor
Incidence of deep vein thrombosis (%)
reviewed to determine whether evidence-based support is sufficient to justify an extended course (>14 days) of anticoagulant prophylaxis after total hip replacement (THR). This study focused on the practical classification of VTEs and the optimal clinical ‘window’ (timeframe) for the use of anticoagulants.
Thromboprophylaxis after THR
Placebo Extended course of lowmolecular-weight heparin
p<0.001 p=0.034 p<0.001
Planes Bergqvist Dahl et al.,37 et al.,57 et al.,2 1996 1996 1997
Lassen et al.,58 1998
Hull et al.,59 2000
Comp et al.,60 2001
Figure The incidence of deep vein thrombosis after total hip arthroplasty in patients receiving an extended course of low-molecular-weight heparin versus placebo, with a mean duration being 34 (range, 30–35) days.32
Journal of Orthopaedic Surgery
Table The postoperative relative risks of symptomatic and overall venous thromboembolism5 Study
Symptomatic venous thromboembolism Low-molecular-weight heparin group No. (%)
Control group No. (%)
Overall venous thromboembolism
Relative risk p Value Low-molecu(95% CI fixed) lar-weight heparin group No. (%)
Planes et 3/90 (3.3) 7/89 (7.9) 0.42 (0.11–1.59) al.,37 1996 Bergqvist et 2/131 (1.5) 10/131 (7.6) 0.20 (0.04–0.90) al.,57 1996 Dahl et 4/117 (3.4) 6/110 (5.5) 0.63 (0.18–2.16) al.,2 1997 Lassen et 2/140 (1.4) 3/141 (2.1) 0.67 (0.11–3.96) al.,58 1998 Hull et 4/389 (1.0) 3/180 (1.7) 0.62 (0.14–2.73) al.,59 2000 Comp et 0/224 (0.0) 7/211 (3.3) 0.06 (0.00–1.09) al.,60 2001 Total 15/1091 (1.4) 36/862 (4.2) 0.36 (0.20–0.67)
bleeding after conventional anticoagulants has been quoted to be 4 to 5 times higher than with placebo,37,57 with a significant increase from 2.5 to 3.7% (RR increase=1.56; 95% CI, 1.08–2.26; NNH=83).62 Minor bleeding events include subcutaneous bruising at the injection site and non-dramatic wound ooze. The major bleeding rate is about 2.5% (95% CI, 1–3%),64 which is not significantly higher than that after placebo.5,32,58,62 Furthermore, major bleeding events occur even less frequently with longer duration of prophylaxis. The daily incidence rates were 1.8% within the first 5 days, and 0.3% after 7 days, and 0.1% at 10 days.65 The efficacy and safety of such prophylaxis increase significantly (p=0.025) beyond 10 days.66 An array of drugs are available for VTE prophylaxis,3,17 from aspirin8,9,17 to warfarin,9,13,15,16,27,28,34,50,67 unfractionated heparin,17,18,28,36,68,69 the factor Xa inhibitor fondaparinux,6,16,29,31,69 and LMWH5,9,16,28,30–32,53 (such as enoxaparin sodium).13,34,37,68,70 Several newer agents targeting novel steps in the coagulation cascade have also been studied.2,3,28,45,46,69,71 Each of these agents carries its own risk profile.35,42,68,72 Therefore, the benefit of VTE reduction must be weighed against the impact of potential adverse events,72,73 including excessive bleeding.9,13,17,67,73 In addition, in a budgetdriven health care environment, cost-per-patient considerations29,51,54,69,74 are important, especially in institutional practices.3,13,70 There is no universally accepted single thromboprophylactic agent of choice.3,16,17 Clinicians are advised to use those that they are most familiar with. An extended course (28–35 days) of enoxaparin sodium, delivered
as a daily subcutaneous injection,6,75 initiated on postoperative day one38,45,46,64 and continued for 4 weeks, is a popular choice, with reduction in DVT and PE rates being 40 to 72% and 46 to 65%, respectively.62,76–78 This agent can be administered to patients in an out-of-hospital setting (e.g. home-visit nursing services) as required, with limited need for haematologic monitoring. The efficacy and safety profile of enoxaparin has been extensively investigated.34,37,47,70,74 Recent advances in oral preparations of LMWHs have simplified its delivery (especially in out-of-hospital settings),3 but rigorous safety and efficacy appraisal is required.
LIMITATIONS The protocol for the time to mobilisation, the use of mechanical anti-thrombotic devices, and the aggressiveness of early physiotherapy vary from institution to institution, as do initiation of preoperative thromboprophylaxis64 and the length of hospital stay. All are related to the frequency of VTE events, but their absolute impact has not yet been supported by level I/II evidence.64 Additional factors limiting generalisability include specialised patient management facilities (other than the expertise/resources available in general settings), small sample size,37,48,50,75 availability of highly sophisticated VTE monitoring approaches (related to external validity),30,45 poorly selected or absent of controls,48 resorting to convenience (nonrandomised) sampling,79 retrospective data,80 poorly
Vol. 18 No. 1, April 2010
defined methodology (limiting reproducibility), and the absence of adequate blinding.
CONCLUSION There is robust evidence to support an extended course (>14 days) of thromboprophylaxis after THR, which confers a RRR of 0.33 to 0.41, even when weighed against the slight increase in adverse events.
Thromboprophylaxis after THR
Sound clinical acumen and judgement is nonetheless important. The extended regimen should provide a baseline, which can be adapted according to the specific circumstances (including clinical indication) of each patient. Clinicians are advised to use the pharmaceuticals that they are most familiar with to cover the high-risk window (postoperative days 14 to 35). The widely used LMWH (enoxaparin sodium) is convenient and reliable, and has a well-documented safety and efficacy profile.
REFERENCES 1. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007;89:799–807. 2. Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26–31. 3. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2008;90:2764–80. 4. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780–5. 5. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858–69. 6. Nutescu EA. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches. Am J Health Syst Pharm 2007;64(11 Suppl 7):S5–13. 7. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009;135:513–20. 8. Gonzalez Della Valle A, Serota A, Go G, Sorriaux G, Sculco TP, Sharrock NE, et al. Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. Clin Orthop Relat Res 2006;444:146–53. 9. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 2003;124(6 Suppl):S349–56. 10. Hooker JA, Lachiewicz PF, Kelley SS. Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty. J Bone Joint Surg Am 1999;81:690–6. 11. Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev 2002;4:CD000305. 12. Kolbach DN, Sandbrink MW, Hamulyak K, Neumann HA, Prins MH. Non-pharmaceutical measures for prevention of postthrombotic syndrome. Cochrane Database Syst Rev 2004;1:CD004174. 13. Míka P, Behounek J, Skotak M, Nevsimal L. Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and warfarin after total replacement of large joints—our experience [in Czech]. Acta Chir Orthop Traumatol Czech 2004;71:237–44. 14. O’Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg 2003;46:129–35. 15. Goldstein WM, Jimenez ML, Bailie DS, Wall R, Branson J. Safety of a clinical surveillance protocol with 3- and 6-week warfarin prophylaxis after total joint arthroplasty. Orthopedics 2001;24:651–4. 16. Conduah A, Lieberman JR. Venous thromboembolic prophylaxis after elective total hip arthroplasty. Clin Orthop Relat Res 2005;441:274–84. 17. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000;82:929–38. 18. Dunn CJ, Goa KL. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. Pharmacoeconomics 1996;10:179–90. 19. Kurtz SM, Ong KL, Schmier J, Mowat F, Saleh K, Dybvik E, et al. Future clinical and economic impact of revision total hip and knee arthroplasty. J Bone Joint Surg Am 2007;89(Suppl 3):S144–51. 20. Weng HH, Fitzgerald J. Current issues in joint replacement surgery. Curr Opin Rheumatol 2006;18:163–9. 21. Biring GS, Masri BA, Greidanus NV, Duncan CP, Garbuz DS. Predictors of quality of life outcomes after revision total hip replacement. J Bone Joint Surg Br 2007;89:1446–51. 22. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. Lancet 2007;370:1508–19.
Journal of Orthopaedic Surgery
23. Ng CY, Ballantyne JA, Brenkel IJ. Quality of life and functional outcome after primary total hip replacement. A five-year follow-up. J Bone Joint Surg Br 2007;89:868–73. 24. Rasanen P, Paavolainen P, Sintonen H, Koivisto AM, Blom M, Ryynanen OP, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop 2007;78:108–15. 25. Jones CA, Beaupre LA, Johnston DW, Suarez-Almazor ME. Total joint arthroplasties: current concepts of patient outcomes after surgery. Rheum Dis Clin North Am 2007;33:71–86. 26. Alfonso DT, Toussaint RJ, Alfonso BD, Strauss EJ, Steiger DT, Di Cesare PE. Nonsurgical complications after total hip and knee arthroplasty. Am J Orthop 2006;35:503–10. 27. Pellegrini VD Jr, Donaldson CT, Farber DC, Lehman EB, Evarts CM. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 2005;441:56–62. 28. Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 2004;64:577–95. 29. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs 2005;5:121–30. 30. Colwell CW Jr, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003;1:2119–30. 31. Colwell C, Mouret P. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Semin Vasc Med 2005;5:266–75. 32. Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg 2007;15:148–55. 33. Dhupar S, Iorio R, Healy WL, Dhimitri K. A comparison of discharge and two-week duplex ultrasound screening protocols for deep venous thrombosis detection following primary total joint arthroplasty. J Bone Joint Surg Am 2006;88:2380–5. 34. Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932–40. 35. Eriksson B. Clinical experience with ximelagatran in orthopaedic surgery. Drugs 2004;64(Suppl 1):S27–35. 36. Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, et al. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). Int Angiol 2006;25:335–42. 37. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224–8. 38. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlebologie. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101–61. 39. Colwell CW Jr. Rationale for thromboprophylaxis in lower joint arthroplasty. Am J Orthop 2007;36(9 Suppl):S11–3. 40. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525–31. 41. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005;87:1675–80. 42. Arcelus JI, Kudrna JC, Caprini JA. Venous thromboembolism following major orthopedic surgery: what is the risk after discharge? Orthopedics 2006;29:506–16. 43. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002;162:1465–71. 44. Dahl OE, Bergqvist D. Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med 2002;8:394–7. 45. Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007;5:746– 53. 46. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103–11. 47. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest 1998;114(Suppl 2):S115–8. 48. Lonner JH, Frank J, McGuire K, Lotke PA. Postthrombotic syndrome after asymptomatic deep vein thrombosis following total knee and hip arthroplasty. Am J Orthop 2006;35:469–72. 49. Anderson FA Jr, White K; Hip and Knee Registry Investigators. Prolonged prophylaxis in orthopaedic surgery: insights from the United States. Semin Thromb Hemost 2002;28(Suppl 3):S43–6. 50. Caprini JA, Arcelus JI, Motykie G, Kudrna JC, Mokhtee D, Reyna JJ. The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J Vasc Surg 1999;30:813–20. 51. Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C, et al. Prolonged thromboprophylaxis with oral
anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002;162:1966– 71. Kessler P. Prevention of venous thromboembolism in orthopaedics [in Czech]. Vnitr Lek 2006;52(Suppl 1):S51–7. Bergqvist D. The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis. Drugs 1996;52(Suppl 7):S55–9. Skedgel C, Goeree R, Pleasance S, Thompson K, O’brien B, Anderson D. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am 2007;89:819–28. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr; Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87–97. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007;64:69–76. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696–700. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res 1998;89:281–7. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a doubleblind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000;160:2208–15. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001;83:336–45. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl): S381–453. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9–15. Wille-Jorgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thromb Haemost 2005;93:236–41. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002;162:1451–6. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. J Thromb Haemost 2003;1:383–4. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. Fondaparinux. J Am Acad Orthop Surg 2004;12:371–5. Tapson VF, Hyers TM, Waldo AL, Ballard DJ, Becker RC, Caprini JA, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005;165:1458–64. Picker SM, Gathof BS. Heparin induced thrombocytopenia. A frequently unrecognised complication after major orthopedic surgery [in German]. Orthopade 2004;33:1300–8. Hawkins D, Huston SA. Pharmacoeconomic considerations in anticoagulant drug use. Expert Opin Pharmacother 2006;7:989–1003. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg 2004;124:507–17. Evans HC, Perry CM, Faulds D. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004;64:649–78. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005;87:2097–112. Whang PG, Lieberman JR. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty. Am J Orthop 2002;31(9 Suppl):S31–6. Anderson DR, O’Brien BJ. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. Pharmacoeconomics 1997;12:17–29. Bergqvist D. Low molecular weight heparins. J Intern Med 1996;240:63–72. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913–30. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913–20. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther 2007;29:2395–405. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;271:1780–5. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 2002;96:1140–6.